Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 7c; Offers FY23 Revenue Guidance
May 4, 2023 8:21 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $38.7 million versus the consensus estimate of $36.3 million.
GUIDANCE:
Karyopharm Therapeutics sees FY2023 revenue of $145-160 million, versus the consensus of... More
